Holen Sie sich die Stockscreener-App
7.01
6.53%
-0.49
Vorhandelsmarkt:
7.00
-0.010
-0.14%
Schlusskurs vom Vortag:
$7.50
Offen:
$7.6
24-Stunden-Volumen:
1.31M
Relative Volume:
4.74
Marktkapitalisierung:
$147.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-33.75
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
+6.37%
1M Leistung:
-4.63%
6M Leistung:
-37.19%
1J Leistung:
-47.44%
1-Tages-Spanne:
$6.8916
$7.70
1-Wochen-Bereich:
$6.25
$7.70
52-Wochen-Spanne:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.01 | 138.56M | 0 | -52.07M | -44.93M | -0.2077 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Acce - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics | CYBN Stock News - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
(CYBN) Investment Analysis - news.stocktradersdaily.com
Cybin, Inc: Covering All Bases as Commercialization Preparations Continue - Smartkarma
Cboe Canada Single Security - Cboe Global Markets
Cybin partners with Thermo Fisher for Phase 3 drug production By Investing.com - Investing.com Nigeria
Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment - simplywall.st
Cybin (CYBN) Collaborates with Thermo Fisher for Phase 3 Development | CYBN Stock News - GuruFocus
CYBN Gains on Thermo Fisher Partnership for CYB003 Production - GuruFocus
AGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset - Endpoints News
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 (CYBN:NYSE) - Seeking Alpha
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program - marketscreener.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Man - GuruFocus
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin partners with Thermo Fisher for Phase 3 drug production - Investing.com
Cybin Inc. Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for Its Cyb003 Program for the Adjunctive Treatment of Major Depressive Disorder - marketscreener.com
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase | CYBN Stock News - GuruFocus
Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment - TipRanks
Cybin (OTCMKTS:CYBN) Shares Down 0.5% – Time to Sell? - Defense World
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin secures new patent for depression treatment drug - Investing.com
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - BioSpace
Cybin (CYBN) Secures U.S. Patent for CYB003 Program | CYBN Stock News - GuruFocus
Cybin secures new patent for depression treatment drug By Investing.com - Investing.com Nigeria
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder - marketscreener.com
Trading (CYBN) With Integrated Risk Controls - news.stocktradersdaily.com
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
Marshall Wace LLP Makes New Investment in Cybin Inc. (NYSE:CYBN) - Defense World
Should You Buy, Sell, or Hold AppLovin Stock Before Q1 Earnings? - The Globe and Mail
Psychedelic drug developer Cybin partners with Osmind - MSN
Cybin (CYBN) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Participate at the 28th Annual Milken Institute Global Conference | CYBN Stock News - GuruFocus
Cybin to Participate at the 28th Annual Milken Institute Global Conference - Bluefield Daily Telegraph
ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI - The Globe and Mail
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin (NYSE:CYBN) Trading Up 2.9% – Here’s What Happened - Defense World
Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa
Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Prog - GuruFocus
Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus
Cybin advances Phase 3 trial for depression treatment - Investing.com
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025 - marketscreener.com
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
1.09%
Kapitalisierung:
|
Volumen (24h):